Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

NCT01059630 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01059630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01059630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2010
Completion date
November 30, 2018
Enrollment
413 (actual)
Sites
121

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma